Human Clinical Trial Demonstrates Aging and Chronic Diseases are a Reversible Data Loss Issue

Abstract

Our human clinical trial observed the cumulative rate of aging, detected biological age, identified anti-aging and reverse aging solutions and effectively neutralized epigenetic issues of human aging as a data loss issue. By sequencing the saliva of our participants, our software and narrow artificial intelligence algorithms juxtaposed changes of DNA methylation positions and other wellness measurements for over a year, and identified specific epigenetic data loss to be the root cause of aging. Chromatin modifiers and histone code relocation causes epigenetic changes in response to DNA damage. In the event that DNA breaks (example, UV radiation), the “silencing proteins” relocate to help repair the DNA damage, and are no longer “silencing” specific portions of DNA, resulting in gene expression changes. Narrow AI results point to solutions with the SIRT2-3 proteins that “switch” and deacetylates (switches “off”) the NLRP3 inflammasome and specific mTOR processes. In young cells, this repairing process is successfully reset upon completion of DNA repair. Aging occurs when the “silencing proteins” fail to correctly return to their home location, leading to gene expression changes and a loss of cellular identity. Groups consuming our “anti-aging” cocktail demonstrated an average of 2.7 years of biological age reversal.

Presenters

Patrick Riley
Chief Scientist, Biotechnology, ODIN, United States

Details

Presentation Type

Innovation Showcase

Theme

Interdisciplinary Health Sciences

KEYWORDS

Aging, Epigenetics, Regenerative Medicine, Wellness measurement, Health technologies, AI, DNA

Digital Media

This presenter hasn’t added media.
Request media and follow this presentation.